New 'Double-Target' cell therapy tested for tough blood cancers
NCT ID NCT04007029
Summary
This early-phase study is testing the safety and best dose of a new type of CAR-T cell therapy for patients with B-cell lymphomas or chronic lymphocytic leukemia that have come back or not responded to standard treatments. Doctors modify a patient's own immune T-cells to recognize two common cancer proteins (CD19 and CD20) instead of one, hoping this makes the therapy more effective. The modified cells are given back to the patient after a short course of chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.